Add Glucokinase Activator to Target A1c

PHASE2CompletedINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

September 30, 2016

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

TTP399 400 mg

once daily

DRUG

TTP399 800 mg

once daily

DRUG

Sitagliptin 100 mg

once daily

DRUG

Placebo

once daily

Trial Locations (20)

23507

Norfolk

27408

Greensboro

29461

Moncks Corner

33409

West Palm Beach

47725

Evansville

55905

Rochester

60031

Gurnee

78154

Schertz

78209

San Antonio

78229

San Antonio

80112

Centennial

80127

Littleton

85213

Mesa

85741

Tuscon

90056

Los Angeles

90255

Huntington Park

91303

Canoga Park

91307

West Hills

99352

Richland

06708

Waterbury

Sponsors

Lead Sponsor

All Listed Sponsors
lead

vTv Therapeutics

INDUSTRY